Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
FDA extends the effective date for the final resolution of DESI 7661 regarding estrogen-androgen fixed-combination drug products, delaying the withdrawal of approval for these products. This provides additional time for manufacturers to comply or seek alternative approvals.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers and generic/ANDA manufacturers of estrogen-androgen fixed-combination drug products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: The extension is effective immediately; the new effective date will be specified in the final rule.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The effective date for the final resolution of DESI 7661 has been extended, delaying the withdrawal of approval for these products.
Who it affects
Branded drug makers and generic/ANDA manufacturers of estrogen-androgen fixed-combination drug products.
What you must do
No immediate action required; monitor for further updates and prepare for eventual compliance or product discontinuation.
Deadline
The extension is effective immediately; the new effective date will be specified in the final rule.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications